CR20150041A - Azaheterociclos como inhibidores de bir2 y/o bir3 - Google Patents

Azaheterociclos como inhibidores de bir2 y/o bir3

Info

Publication number
CR20150041A
CR20150041A CR20150041A CR20150041A CR20150041A CR 20150041 A CR20150041 A CR 20150041A CR 20150041 A CR20150041 A CR 20150041A CR 20150041 A CR20150041 A CR 20150041A CR 20150041 A CR20150041 A CR 20150041A
Authority
CR
Costa Rica
Prior art keywords
azaheterociclos
bir2
bir3
inhibitors
compounds
Prior art date
Application number
CR20150041A
Other languages
English (en)
Inventor
Joan Heather Hogg
Kang Le
Yan Lou
Steven Gregory Mischke
Stacy Remiszewski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48948413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20150041A publication Critical patent/CR20150041A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se dan a conocer compuestos de fórmula (I) o sales farmacéuticamente aceptables de los mismos, en la que R1, R2, R3, m, n y q se definen en la presente solicitud, y métodos de utilización de dichos compuestos en el tratamiento del cáncer.
CR20150041A 2012-08-15 2015-01-29 Azaheterociclos como inhibidores de bir2 y/o bir3 CR20150041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261683253P 2012-08-15 2012-08-15
PCT/EP2013/066458 WO2014026882A1 (en) 2012-08-15 2013-08-06 Azaheterocycles as bir2 and/or bir3 inhibitors

Publications (1)

Publication Number Publication Date
CR20150041A true CR20150041A (es) 2015-03-13

Family

ID=48948413

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150041A CR20150041A (es) 2012-08-15 2015-01-29 Azaheterociclos como inhibidores de bir2 y/o bir3

Country Status (21)

Country Link
US (1) US9422332B2 (es)
EP (1) EP2885275A1 (es)
JP (1) JP6203261B2 (es)
KR (1) KR20150042792A (es)
CN (1) CN104540806B (es)
AU (1) AU2013304214A1 (es)
BR (1) BR112015003201A2 (es)
CA (1) CA2878106A1 (es)
CL (1) CL2015000333A1 (es)
CO (1) CO7180196A2 (es)
CR (1) CR20150041A (es)
EA (1) EA201590347A1 (es)
HK (1) HK1209427A1 (es)
IL (1) IL237063A0 (es)
MA (1) MA37896A1 (es)
MX (1) MX2015001905A (es)
PE (1) PE20150674A1 (es)
PH (1) PH12015500185B1 (es)
SG (1) SG11201500581WA (es)
WO (1) WO2014026882A1 (es)
ZA (1) ZA201500342B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
ES2899002T3 (es) * 2016-03-22 2022-03-09 Inst Nat Sante Rech Med Nuevos derivados y su uso como inhibidores selectivos de Caspasa-2
US10398702B2 (en) * 2016-05-09 2019-09-03 Hoffmann-La Roche Inc. Dimeric compounds
CN106265764B (zh) 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101094833A (zh) * 2004-07-12 2007-12-26 伊邓药品公司 四肽类似物
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
US8551955B2 (en) * 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics

Also Published As

Publication number Publication date
CL2015000333A1 (es) 2015-11-06
KR20150042792A (ko) 2015-04-21
PH12015500185A1 (en) 2015-04-20
US20150210739A1 (en) 2015-07-30
EA201590347A1 (ru) 2015-05-29
IL237063A0 (en) 2015-03-31
MX2015001905A (es) 2015-06-05
JP2015526436A (ja) 2015-09-10
WO2014026882A1 (en) 2014-02-20
JP6203261B2 (ja) 2017-09-27
AU2013304214A1 (en) 2015-02-12
US9422332B2 (en) 2016-08-23
CN104540806A (zh) 2015-04-22
ZA201500342B (en) 2017-09-27
BR112015003201A2 (pt) 2017-07-04
CN104540806B (zh) 2017-05-03
EP2885275A1 (en) 2015-06-24
CA2878106A1 (en) 2014-02-20
MA37896A1 (fr) 2016-09-30
SG11201500581WA (en) 2015-04-29
CO7180196A2 (es) 2015-02-09
HK1209427A1 (en) 2016-04-01
PE20150674A1 (es) 2015-05-06
PH12015500185B1 (en) 2015-04-20

Similar Documents

Publication Publication Date Title
CO7350640A2 (es) Compuestos diméricos
CR20120418A (es) Inhibidores de virus flaviviridae
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CO7160104A2 (es) Inhibidores de virus de hepatitis c
DOP2014000203A (es) Compuestos de heterociclilo
ECSP15000435A (es) Inhibidores macrocíclicos de virus flaviviridae
CL2015000711A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
CR20150250A (es) Nuevos derivados de piridina
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
CR20150041A (es) Azaheterociclos como inhibidores de bir2 y/o bir3
DOP2015000060A (es) Profármacos de aminoquinazolina inhibidora de cinasa
ECSP14011792A (es) Inhibidores de iap
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
CR20150148A (es) Azaindolinas
BR112014012521A2 (pt) novos derivados de pirrolidina como inibidores de catepsina
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
BR112014019220A8 (pt) Novos derivados de pirrolidina